Research ExplorerPublicationsUpdate Breast Cancer 2022 Part 5 - Early Stage Breast Cancer

Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer

Standard

Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer. / Fehm, Tanja N; Welslau, Manfred; Müller, Volkmar; Lüftner, Diana; Schütz, Florian; Fasching, Peter A; Janni, Wolfgang; Thomssen, Christoph; Witzel, Isabell; Beierlein, Milena; Belleville, Erik; Untch, Michael; Thill, Marc; Tesch, Hans; Ditsch, Nina; Lux, Michael P; Aktas, Bahriye; Banys-Paluchowski, Maggie; Kolberg-Liedtke, Cornelia; Hartkopf, Andreas D; Wöckel, Achim; Kolberg, Hans-Christian; Harbeck, Nadia; Stickeler, Elmar.

In: GEBURTSH FRAUENHEILK, Vol. 83, No. 3, 03.2023, p. 289-298.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Fehm, TN, Welslau, M, Müller, V, Lüftner, D, Schütz, F, Fasching, PA, Janni, W, Thomssen, C, Witzel, I, Beierlein, M, Belleville, E, Untch, M, Thill, M, Tesch, H, Ditsch, N, Lux, MP, Aktas, B, Banys-Paluchowski, M, Kolberg-Liedtke, C, Hartkopf, AD, Wöckel, A, Kolberg, H-C, Harbeck, N & Stickeler, E 2023, 'Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer', GEBURTSH FRAUENHEILK, vol. 83, no. 3, pp. 289-298. https://doi.org/10.1055/a-2018-9053

APA

Fehm, T. N., Welslau, M., Müller, V., Lüftner, D., Schütz, F., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., Beierlein, M., Belleville, E., Untch, M., Thill, M., Tesch, H., Ditsch, N., Lux, M. P., Aktas, B., Banys-Paluchowski, M., Kolberg-Liedtke, C., ... Stickeler, E. (2023). Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer. GEBURTSH FRAUENHEILK, 83(3), 289-298. https://doi.org/10.1055/a-2018-9053

Vancouver

Fehm TN, Welslau M, Müller V, Lüftner D, Schütz F, Fasching PA et al. Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer. GEBURTSH FRAUENHEILK. 2023 Mar;83(3):289-298. https://doi.org/10.1055/a-2018-9053

Bibtex

@article{883e10c4269b4d7aa40a863eb149b4f3,
title = "Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer",
abstract = "The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.",
author = "Fehm, {Tanja N} and Manfred Welslau and Volkmar M{\"u}ller and Diana L{\"u}ftner and Florian Sch{\"u}tz and Fasching, {Peter A} and Wolfgang Janni and Christoph Thomssen and Isabell Witzel and Milena Beierlein and Erik Belleville and Michael Untch and Marc Thill and Hans Tesch and Nina Ditsch and Lux, {Michael P} and Bahriye Aktas and Maggie Banys-Paluchowski and Cornelia Kolberg-Liedtke and Hartkopf, {Andreas D} and Achim W{\"o}ckel and Hans-Christian Kolberg and Nadia Harbeck and Elmar Stickeler",
note = "The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).",
year = "2023",
month = mar,
doi = "10.1055/a-2018-9053",
language = "English",
volume = "83",
pages = "289--298",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "3",

}

RIS

TY - JOUR

T1 - Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer

AU - Fehm, Tanja N

AU - Welslau, Manfred

AU - Müller, Volkmar

AU - Lüftner, Diana

AU - Schütz, Florian

AU - Fasching, Peter A

AU - Janni, Wolfgang

AU - Thomssen, Christoph

AU - Witzel, Isabell

AU - Beierlein, Milena

AU - Belleville, Erik

AU - Untch, Michael

AU - Thill, Marc

AU - Tesch, Hans

AU - Ditsch, Nina

AU - Lux, Michael P

AU - Aktas, Bahriye

AU - Banys-Paluchowski, Maggie

AU - Kolberg-Liedtke, Cornelia

AU - Hartkopf, Andreas D

AU - Wöckel, Achim

AU - Kolberg, Hans-Christian

AU - Harbeck, Nadia

AU - Stickeler, Elmar

N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).

PY - 2023/3

Y1 - 2023/3

N2 - The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.

AB - The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.

U2 - 10.1055/a-2018-9053

DO - 10.1055/a-2018-9053

M3 - SCORING: Journal article

C2 - 36908285

VL - 83

SP - 289

EP - 298

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 3

ER -